Computer-based cognitive tests and cerebral pathology among Japanese older adults
-
Published:2023-04-10
Issue:1
Volume:23
Page:
-
ISSN:1471-2318
-
Container-title:BMC Geriatrics
-
language:en
-
Short-container-title:BMC Geriatr
Author:
Shimada Hiroyuki,Makino Keitaro,Kato Takashi,Ito Kengo
Abstract
Abstract
Background
This study aimed to identify the appropriate computer-based cognitive tests and cut-off values for estimating amyloid burden in preclinical Alzheimer’s disease drug trials.
Methods
Data from 103 older individuals, who underwent 18F-florbetapir positron emission tomography and cognitive testing, were analyzed. Cognitive tests evaluated word list memory (immediate recognition and delayed recall), attention (Trail Making Test-part A), executive function (Trail Making Test-Part B), and processing speed (Digit Symbol Substitution Test [DSST]).
Results
The Aβ burden was significantly associated with word list memory (odds ratio [OR] = 0.42, 95% confidence interval [CI], 0.19–0.91) and DSST (OR = 0.35; 95% CI, 0.14–0.85). Positive predictive value and number needed to screen at a cut-off of 1.5 SD were better for word list memory and DSST among predictive values.
Conclusions
The computer-based memory and processing speed tests have the potential to reduce failure rates while screening individuals with Aβ accumulation in community settings.
Funder
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Subject
Geriatrics and Gerontology
Reference21 articles.
1. Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, et al. What have we learned from expedition III and EPOCH Trials? Perspective of the CTAD Task Force. J Prev Alzheimers Dis. 2018;5(3):171–4. 2. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92. 3. Sperling RA, Donohue MC, Raman R, Sun CK, Yaari R, Holdridge K, Siemers E, Johnson KA, Aisen PS, Team AS. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA neurology. 2020;77(6):735–45. 4. Shen XN, Li JQ, Wang HF, Li HQ, Huang YY, Yang YX, Tan L, Dong Q, Yu JT. Alzheimer’s Disease Neuroimaging I: Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer’s disease pathology and clinical progression in older adults without dementia. Alzheimers Dement (Amst). 2020;12(1):e12104. 5. Shimada H, Makizako H, Doi T, Yoshida D, Tsutsumimoto K, Anan Y, Uemura K, Ito T, Lee S, Park H, et al. Combined prevalence of frailty and mild cognitive impairment in a population of elderly Japanese people. J Am Med Dir Assoc. 2013;14(7):518–24.
|
|